Inhibitor of Apoptosis (IAP) proteins as drug targets for the treatment of cancer.
Source TitleF1000 biology reports
PublisherFaculty Opinions Ltd
University of Melbourne Author/sVaux, David
AffiliationMedical Biology (W.E.H.I.)
Document TypeJournal Article
CitationsVaux, D. L. (2009). Inhibitor of Apoptosis (IAP) proteins as drug targets for the treatment of cancer.. F1000 Biol Rep, 1, pp.79-. https://doi.org/10.3410/B1-79.
Access StatusOpen Access
Open Access at PMChttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948278
Three companies, Genentech, Aegera Therapeutics/Human Genome Sciences, and Novartis, have commenced phase 1 clinical trials of inhibitor of apoptosis (IAP) antagonist 'Smac mimetic' compounds for the treatment of cancer. These trials represent the culmination of a line of research that commenced with analysis of how insect viruses stop host cells from killing themselves and led to the discovery of a family of proteins that regulate development in insects and signalling by tumour necrosis factor superfamily members in mammals, which prompted development of drugs that mimic natural IAP-binding proteins to promote cell death.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References